Loading...
Optimizing (neo)adjuvant treatment of HER2-positive breast cancer
The development of human epidermal growth factor 2 (HER2)-directed therapy has resulted in significant improvement in outcomes for patients with early-stage HER2-overexpressing (HER2+) breast cancer. In recent years, newer HER2-directed agents and novel treatment strategies have been developed with...
Na minha lista:
| Udgivet i: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6048669/ https://ncbi.nlm.nih.gov/pubmed/30034547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835918775697 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|